Podcasts about fhfsa

Sara Paul, DNP, FNP, FAHA, CHFN, FHFSA, discusses the association between sudden death and heart failure with reduced ejection fraction, and actions for aggressive treatment and management of heart failure will be presented. In addition, she describes device therapy for the prevention of sudden death.

It is an exciting time in cardiovascular prevention and management, where we can work together to make a significant difference for our patients. New pharmacotherapies are changing the disease burden and leading to improved outcomes for our patients, regardless of circumstance. Guest Clyde Yancy, MD, MSc, MACC, MACP, FAH, FHFSA, FRCP, FASPC (Hon.), FPCNA (Hon.), provides data and inspiration for our actions every day. SELECT Trial: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/11/09/15/04/select Health Equity Self-Assessment Tool: Take 10 minutes, identify your strengths, and get links to related resources. https://pcna.net/clinical-resources/provider-tools/health-equity-provider-tools/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jo Ellen Rodgers, PharmD, BCPS, BCCP, FCCP, FHFSA, FAHA, CPP, is Professor and Vice Chair of Professional Education and Practice for the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy. She was also the recipient of the 2022 ACCP Cardiology PRN Lifetime Achievement Award.Dr. Rodgers has always been a joy to talk to and you'll see why on this episode. We talk about how her clinical practice drives her research and teaching in academia and how she transitioned from UNC Medical Center's acute care cardiology to ambulatory care cardio-oncology. As with any career, even those awarded lifetime achievement awards, there can be barriers to overcome and we talk through what those were for her and how your work life impacts your personal life and vice versa. We packed a lot into this episode and it's one you won't want to miss!

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN There are 4 stages of heart failure, ranging from being at risk for heart failure to having an advanced condition. So what key insights should we know about the ACC/AHA stages of heart failure and the NYHA heart failure functional classifications? Discover more with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN There are 4 stages of heart failure, ranging from being at risk for heart failure to having an advanced condition. So what key insights should we know about the ACC/AHA stages of heart failure and the NYHA heart failure functional classifications? Discover more with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation.

Drs Michelle Kittleson and James Fang cap off the podcast series by discussing difficult cardiac transplantation decision points, including LVADs and the latest innovations in cardiac transplantation. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982166). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Heart Failure https://emedicine.medscape.com/article/163062-overview Heart Transplantation https://emedicine.medscape.com/article/429816-overview Lynne Warner Stevenson, MD, FHFSA https://hfsa.org/lynne-warner-stevenson-md-fhfsa Risk Prediction Models for Survival After Heart Transplantation: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31733026/ Evaluation for Heart Transplantation and LVAD Implantation https://njadvancedheartfailure.com/wp-content/uploads/2022/04/Zucker-Heart-Transplantation-and-LVAD-Indications.pdf Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/30852913/ Left Ventricular Assist Devices https://www.ncbi.nlm.nih.gov/books/NBK499841/ The Burden of Haemocompatibility With Left Ventricular Assist Systems: A Complex Weave https://pubmed.ncbi.nlm.nih.gov/28329374/ Guidance and Policy Clarifications Addressing Adult Heart Allocation Policy https://optn.transplant.hrsa.gov/media/3931/guidance_policy_clarifications_address_adult_heart_allocation_policy.pdf Heart Transplantation From Donation After Circulatory Determined Death https://pubmed.ncbi.nlm.nih.gov/29492385/ Destination Therapy With Left Ventricular Assist Devices in Non-Transplant Centres: The Time Is Right https://pubmed.ncbi.nlm.nih.gov/32419850/ Frailty and the Selection of Patients for Destination Therapy Left Ventricular Assist Device https://pubmed.ncbi.nlm.nih.gov/22438521/ Heart Transplant Advances: Ex Vivo Organ-Preservation Systems https://pubmed.ncbi.nlm.nih.gov/36004090/ First Clinical Experience With the Novel Cold Storage Sherpapak™ System for Donor Heart Transportation https://pubmed.ncbi.nlm.nih.gov/33447411/ Is the Organ Care System (OCS) Still the First Choice With Emerging New Strategies for Donation After Circulatory Death (DCD) in Heart Transplant? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229932/

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Michael Dickinson, MD, FACC, FHFSA - board-certified Cardiologist and Heart Failure Specialist answers questions on initiating GDMT-4 and reducing HF hospitalizations.

Review resources for healthcare professionals and their patients with ATTR-CM, including written/electronic references, websites, mentors, organizations, support groups, clinical trials, and specialty clinics. Episode guests Janell Grazzine Frantz, CNP, APRN, MSN, and Johana Fajardo, DNP, ANP-BC, CHFN, FHFSA, with moderator Kim Newlin, MSN, ANP, FPCNA.Heart Failure Society of America: https://hfsa.org/Amyloidosis Support Groups: https://www.amyloidosissupport.org/International Society of Amyloidosis https://www.isaamyloidosis.org/American Society of Heart Failure Nurses https://www.aahfn.org/A Guide for the Diagnosis and Management of Amyloidosis: https://www.aahfn.org/store/viewproduct.aspx?id=16410228Mayo Clinic - amyloidosis: https://www.mayoclinic.org/diseases-conditions/amyloidosis/diagnosis-treatment/drc-20353183See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the DANCAVAS Trial, researchers found a remarkable reduction in death of any cause, and this might be a game changer in prevention of cardiovascular diseases. In this interview, Axel Cosmus Pyndt Diederichsen MD and Clyde W. Yancy MD, MSc, MACC, FAHA, MACP, FHFSA, FASPC (Hon.) discuss ESC Late-Breaker: DANCAVAS: screening and intervention to prevent cardiovascular disease. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

[CE contact hours--see below.] Often prescribed for obesity, SGLT2is and GLP-1 RAs have a role in heart failure management. Learn about their mechanisms of action, and how their use extends beyond weight loss to cardioprotective and renalprotective properties. Guests: Kim Newlin, MSN, ANP, FPCNA, of Sutter Roseville Medical Center in Northern California, and Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA, from the University of Colorado in Denver. CE Link: https://pcna.net/?p=10718&post_type=online-course&preview_id=10718 2022 AHA/ACC/HFSA 2022 Guideline for the Managment of HF: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063Pocket Guide: Guidelines for Managing CVD Risk in Patients with Diabetes: https://pcna.net/clinical-resources/provider-tools/diabetes-provider-tools/HF Pocket Guide: A Guide to Prevention and Management: https://pcna.net/clinical-resources/provider-tools/heart-failure-provider-tools/ New and Emerging Treatments for Heart Failure: HFrEF and HFpEF (CE course): https://pcna.net/online-course/new-and-emerging-treatments-for-heart-failure-hfref-and-hfpef/ SGLT2is in Heart Failure: ncbi.nlm.nih.gov/pmc/articles/PMC8654149/SGLT2i in HFpEF: multicenter randomized trial: nature.com/articles/s41591-021-01536-xEmpagliflozin in HFpEF: https://www.nejm.org/doi/10.1056/NEJMoa2107038#:~:text=Empagliflozin%20in%20HF%20with%20Preserved%20Ejection%20Fraction&text=Sodium%E2%80%93glucose%20cotransporter%202%20(SGLT2,and%20a%20reduced%20ejection%20fraction. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

[CE contact hours--see below.] Improving quality of life for patients with heart failure can include lifestyle modifications and require successful behavior change strategies. Learn best practices to apply into your clinical setting from nurse providers Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA, of the University of Colorado in Denver, and Binu Koirala, PhD, MGS, RN, of the Johns Hopkins University School of Nursing in Baltimore.CE LINK: https://pcna.net/?p=10717&post_type=online-course&preview_id=10717PCNA Behavior Change mini-certifice (CE course): https://pcna.net/professional-development/online-learning/ "Behavior Change mini-certificate"AHA HF Tools & Resources: heart.org/en/health-topics/heart-failure/heart-failure-tools-resourcesAdherence to Healthy Sleep Patterns: ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050792?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&Addressing Social Determinants of Health in Patients with HF: ahajournals.org/doi/10.1161/CIR.0000000000000767See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.naceonline.com/courses/managing-hfpef-incorporating-evolving-data-into-practice-2-new-data-and-evolving-strategiesFeaturing  speaker Javed Butler, MD, MPH, MBA, moderated by Alanna Morris, MD, MSc, FHFSA, FACC, FAHA, and contributing faculty Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACPSummaryApproximately 50% of patients with heart failure (HF) have preserved ejection fraction (HFpEF), and the prevalence of HFpEF relative to HF with reduced ejection fraction (HFrEF) has been increasing by about 1% per year. If this trend continues, HFpEF will become the most common type of HF in the near future. Early diagnosis and treatment of HFpEF are important to help prevent hospitalizations and complications, especially because new treatment options are available that improve outcomes for patients with HFpEF.In this 3-part educational podcast series moderated by Dr. Alanna Morris, expert faculty discuss the management of HFpEF and incorporating evolving data into practice. In part 2, Dr. Javed Butler and Dr. Alanna Morris discuss the latest data regarding new and emerging therapies for the treatment of HFpEF.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Discuss evolving data for managing patients with chronic HFpEFThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.naceonline.com/courses/managing-hfpef-incorporating-evolving-data-into-practice-2-new-data-and-evolving-strategiesThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.naceonline.com/courses/managing-hfpef-incorporating-evolving-data-into-practice-3-an-evolving-algorithmFeaturing speaker Javed Butler, MD, MPH, MBA, moderated by Alanna Morris, MD, MSc, FHFSA, FACC, FAHA, and contributing faculty Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACPSummaryApproximately 50% of patients with heart failure (HF) have preserved ejection fraction (HFpEF), and the prevalence of HFpEF relative to HF with reduced ejection fraction (HFrEF) has been increasing by about 1% per year. If this trend continues, HFpEF will become the most common type of HF in the near future. Early diagnosis and treatment of HFpEF are important to help prevent hospitalizations and complications, especially because new treatment options are available that improve outcomes for patients with HFpEF.In this 3-part educational podcast series moderated by Dr. Alanna Morris, expert faculty discuss the management of HFpEF and incorporating evolving data into practice. In part 3, Dr. Javed Butler and Dr. Alanna Morris discuss best practices for integrating new and emerging therapies into the management of patients with HFpEF.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Integrate current and emerging data into the management of patients with chronic HFpEFThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.naceonline.com/courses/managing-hfpef-incorporating-evolving-data-into-practice-3-an-evolving-algorithmThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.naceonline.com/courses/managing-hfpef-incorporating-evolving-data-into-practice-1-heart-failure-new-definitions-and-classificationsFeaturing speaker Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP, moderated by Alanna Morris, MD, MSc, FHFSA, FACC, FAHA, and contributing faculty Javed Butler, MD, MPH, MBASummaryApproximately 50% of patients with heart failure (HF) have preserved ejection fraction (HFpEF), and the prevalence of HFpEF relative to HF with reduced ejection fraction (HFrEF) has been increasing by about 1% per year. If this trend continues, HFpEF will become the most common type of HF in the near future. Early diagnosis and treatment of HFpEF are important to help prevent hospitalizations and complications, especially because new treatment options are available that improve outcomes for patients with HFpEF.In this 3-part educational podcast series moderated by Dr. Alanna Morris, expert faculty discuss the management of HFpEF and incorporating evolving data into practice. In part 1, Dr. Biykem Bozkurt and Dr. Alanna Morris describe the updated universal definition of HF, which has implications for improving HF diagnosis, assessment, and management.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Describe the updated universal definition of HFThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.naceonline.com/courses/managing-hfpef-incorporating-evolving-data-into-practice-1-heart-failure-new-definitions-and-classificationsThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Host: Javed Butler, MD, MBA, MPH Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Based on the 2021 American College of Cardiology Expert Consensus Decision Pathway recommendations, it might be time to rethink our approach to heart failure. But what exactly do the latest recommendations say regarding the role of angiotensin receptor-neprilysin inhibitors (ARNis) in the treatment of heart failure with reduced ejection fraction? Joining Dr. Javed Butler to answer that key question is Dr. Nancy Albert.

SummaryFor more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Risk Assessment in Pulmonary Arterial Hypertension and Right Heart Failure: Individualizing Therapy PodcastIn this podcast episode, Dr. Raymond L. Benza and Dr. Alanna Morris will discuss early diagnosis, effective monitoring, and new treatment approaches to ensure timely treatment and to optimize the management of patients with PAH and RHF.Pulmonary arterial hypertension (PAH) is a progressive and life-threatening condition for which early diagnosis and treatment are crucial. However, early recognition of PAH can be challenging because the disease does not become clinically manifest until pulmonary vascular disease is advanced. Right heart failure (RHF) is the most common cause of death in PAH patients, and newer treatments are available that can reduce right ventricular afterload, improve exercise capacity, and improve quality of life. In addition, clinicians may not have an algorithm for PAH management and may be unclear about PAH treatment goals, management strategies, and monitoring for disease activity. This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Utilize updated definitions and diagnostic evaluations to recognize patients with PAH.Incorporate evidence for new and emerging treatments into the management of patients with PAH and RHF.This activity is accredited for CME/CE credit.  For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Risk Assessment in Pulmonary Arterial Hypertension and Right Heart Failure: Individualizing Therapy PodcastSpeakerRaymond L. Benza, MD, FACC, FAHA, FCCPProfessor of MedicineBob and Corrine Frick Chair of Heart FailureDivision of Cardiovascular MedicineThe Ohio State UniversityColumbus, OHModerator/Course DirectorAlanna Morris, MD, MSc, FHFSA, FACC, FAHAAssociate Professor of Medicine, Division of CardiologyDirector of Heart Failure ResearchEmory University Clinical Cardiovascular Research InstituteEmory University School of MedicineAtlanta, GAPlanning CommitteeSandy Bihlmeyer, MEdSenior Project ManagerNational Association for Continuing EducationPlantation, FLMichelle Frisch, MPHVice President, OperationsNational Association for Continuing EducationPlantation, FLAngela Golden, DNP, FNP-C, FAANPFamily Nurse PractitionerNP Obesity Treatment Clinic and NP from Home, LLCAssistant Professor (Ret), Northern Arizona UniversityPast President, American Association of Nurse PractitionersMunds Park, AZDaniela HiedraActivity DirectorNational Association for Continuing EducationPlantation, FLJoshua F. KilbridgePresident and Creative Director Kilbridge AssociatesSan Francisco, CAGregg Sherman, MDChief Medical OfficerCourse DirectorNational Association for Continuing EducationPlantation, FLProvided ByNational Association for Continuing EducationNACE Accreditation StatementThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide c

Host Kevin Shah, MD is joined by guest host Nosheen Reza, MD, to interview the winners of the 2021 HFSA Lifetime Achievement Award -  Inder Anand, MD,  PhD, and Lynne Warner Stevenson, MD, FHFSA. The episode was recorded live onsite at the HFSA Annual Scientific Meeting 2021, September 10-13 in Denver, Colorado.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Advances in HFrEF: Slowing a Poor Hospital Prognosis, Part 2 - Evidence-Based Management PodcastFeaturing James L. Januzzi Jr., MD, FACC, FESC as faculty, moderated by Alanna Morris, MD, MSc, FHFSA, FACC, FAHA.SummaryIn this 2-part educational podcast series, Dr. James Januzzi and Dr. Alanna Morris discuss new therapies and treatment strategies for management of patients with heart failure and reduced ejection fraction (HFrEF). In part 2, the faculty review new developments in the management of and guideline-directed medical therapy for patients with HFrEF.Heart failure (HF) accounts for around one million hospitalizations in the United States every year, and approximately 50% of these are caused by HF with reduced ejection fraction (HFrEF). Optimal care for patients with HFrEF continues to be refined with the recent advancements in drug and device therapies that can reduce the incidence of cardiovascular (CV) death or hospitalization and improve the prognosis of patients with HFrEF. Clinicians need updated information regarding these recent advancements, when and how to use them, and recommendations for adhering to guideline-directed medical therapies (GDMT) for HF.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Apply evidence-based GDMT when treating patients with chronic heart failure, including up-titration of medications to meet recommended target levelsIdentify patient populations with symptomatic, chronic HFrEF who would benefit from newer agents, based on safety and efficacy data and individual patient characteristicsThis activity is accredited for CME/CE credit. For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Advances in HFrEF: Slowing a Poor Hospital Prognosis, Part 2 - Evidence-Based Management PodcastThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Advances in HFrEF: Slowing a Poor Hospital Prognosis, Part 1- Stratifying Risk PodcastFeaturing James L. Januzzi Jr., MD, FACC, FESC as faculty, moderated by Alanna Morris, MD, MSc, FHFSA, FACC, FAHA.SummaryIn this 2-part educational podcast series, Dr. James Januzzi and Dr. Alanna Morris discuss new therapies and treatment strategies for management of patients with HF and reduced ejection fraction (HFrEF). In part 1, the faculty review aspects of risk stratification in patients with HFrEF and why stratifying risk for these patients is so important.Heart failure (HF) accounts for around one million hospitalizations in the United States every year, and approximately 50% of these are caused by HF with reduced ejection fraction (HFrEF). Optimal care for patients with HFrEF continues to be refined with the recent advancements in drug and device therapies that can reduce the incidence of cardiovascular (CV) death or hospitalization and improve the prognosis of patients with HFrEF. Clinicians need updated information regarding these recent advancements, when and how to use them, and recommendations for adhering to guideline-directed medical therapies (GDMT) for HF.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Identify disease and patient characteristics that increase the risk of re-hospitalization or CV death in people with heart failureThis activity is accredited for CME/CE credit. For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Advances in HFrEF: Slowing a Poor Hospital Prognosis, Part 1- Stratifying Risk PodcastThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Heart failure (HF) accounts for nearly 2 hospitalizations every minute in the U.S. Beth Davidson, a HF nurse practitioner in Nashville, TN, and President of the American Association of HF Nurses discusses HF, symptoms, the seriousness of HF hospitalization, and treatment and lifestyle tips that may help patients or a loved one manage the condition. She is joined by Kim , who at 32 was shocked to be diagnosed with HF. She is now 53 and shares her story and how she is successfully managing her HF today. Beth Davidson, DNP, ACNP, CHFN, CCRN, FHFSA. Beth Towery Davidson is Director of the Heart Failure Disease Management Program at TriStar Centennial Medical Center in Nashville, TN. She is also adjunct faculty for Vanderbilt University School of Nursing. She has more than 20 years' experience in cardiac and critical care nursing, and has worked as a clinical nurse specialist, heart transplant coordinator, and nurse practitioner providing care to patients with cardiac diagnoses. She has published and presented on the topics of heart failure, mechanical circulatory support, and transplantation. Beth is currently serving her second term as President of the American Association of Heart Failure Nurses. #HeartFailure

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/managing-heart-failure-in-primary-care-podcastFeaturing Alanna Morris, MD, MSc, FHFSA, FACC, FAHA as faculty, moderated by Gregg Sherman, MD.This course will review evidence-based guidelines for early recognition and diagnosis of Heart Failure (HF), development of patient care plans that consider the latest guidelines and clinical data, as well as patient characteristics,  and the benefits of a multi-disciplinary team and shared-decision making approach to improve patient outcomes. Heart failure (HF) is a growing problem that affects an estimated 6.2 million adults in the United States. The availability of effective medical therapies for HF, including newer agents, offers the prospect of improved outcomes. However, HF remains underdiagnosed, and the assessment and management of HF patients may not align with evidence-based guidelines. Primary care providers (PCPs) are frequently the first line of care for patients with HF and are frequently responsible for making timely and accurate diagnoses, initiating therapy, and managing comorbidities. This activity is certified for CME/CE credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/managing-heart-failure-in-primary-care-podcastAssociation of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 21222. This activity is approved for 0.5 contact hours (which includes 0 hours of pharmacology).This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.